Phoenix、AZにおける過体重の臨床試験
Phoenixとその周辺地域（約30マイル以内）の拠点で、過体重に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
被験者募集中第3相
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
被験者募集中第3相
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
被験者募集中第3相
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
被験者募集中第3相
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
被験者募集中第3相
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
被験者募集中第3相
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
被験者募集中第3相
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
被験者募集中第2相
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
被験者募集中第3相健康なボランティア歓迎
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
被験者募集中第2相
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
被験者募集中第4相
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
被験者募集中第3相
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
被験者募集中観察研究
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
被験者募集中第3相
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
被験者募集中第3相
- The University of Arizona College of Medicine- Phoenix, Phoenix
他の都市における過体重の試験
- San Antonio, TX34件の研究
- Houston, TX33件の研究
- Chicago, IL28件の研究
- Orlando, FL27件の研究
- Las Vegas, NV23件の研究
- Miami, FL23件の研究
- Atlanta, GA20件の研究
- Dallas, TX20件の研究
- New York City, NY19件の研究
- Jacksonville, FL19件の研究
- Washington, DC19件の研究
- Austin, TX18件の研究
Phoenixにおける他の研究
- 乳がん25件の研究
- 大腸癌25件の研究
- 肥満症22件の研究
- 非小細胞肺癌20件の研究
- 転移性癌20件の研究
- 心不全18件の研究
- 前立腺がん17件の研究
- がん（全種類）17件の研究
- 多発性骨髄腫16件の研究
- 膵臓がん16件の研究
- 心血管疾患16件の研究
- アルツハイマー病15件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。